EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2009 Results
10 March 2010 - 5:00PM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today details relating to its fourth quarter
and full year 2009 results announcement, which will take place on
Tuesday, March 30, 2010, before the opening of the market.
EDAP will hold a conference call on Tuesday, March 30, 2010 at
8:30 a.m. ET to discuss the results. The dial-in numbers are (877)
407-4134 for domestic callers and (201) 689-8430 for international.
The conference ID number for both is 00346818. A live Webcast of
the conference call will be available online from the investor
relations page of the Company's corporate Website at
www.edap-tms.com.
After the live Webcast, the call will remain available on EDAP's
Website, www.edap-tms.com, through June 30, 2010. In addition, a
telephonic replay of the call will be available until April 5,
2010. The replay dial-in numbers are 877-660-6853 for domestic
callers and 201-612-7415 for international callers. Please use
account number 356 and event ID number 346818.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm, the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multicenter U.S. Phase II/III clinical
trial under an Investigational Device Exemption granted by the FDA,
the ENLIGHT U.S. clinical study. The Company also is developing
this technology for the potential treatment of certain other types
of tumors. EDAP TMS SA also produces and commercializes medical
equipment for treatment of urinary tract stones using
extra-corporeal shockwave lithotripsy (ESWL). For more information
on the company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com and http://www.pcaresearch.com.
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024